Adam P. Jones

Oxford Road
Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Characterizing Tumor-Induced Ataxia in a Vestibular Schwannoma Mouse Model.

Characterizing Tumor-Induced Ataxia in a Vestibular Schwannoma Mouse Model.

Journal: Journal of visualized experiments : JoVE

Published: March 09, 2026

Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy.

Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy.

Journal: International journal of molecular sciences

Published: December 03, 2025

A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation.

A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation.

Journal: Theranostics

Published: August 14, 2025

The tumour immune microenvironment is enriched but suppressed in vestibular schwannoma compared to meningioma: therapeutic implications for NF2-related schwannomatosis.

The tumour immune microenvironment is enriched but suppressed in vestibular schwannoma compared to meningioma: therapeutic implications for NF2-related schwannomatosis.

Journal: Acta neuropathologica communications

Published: July 22, 2025

Characterizing the effects of anti-PD1 immunotherapy on ataxia in a vestibular schwannoma mouse model.

Characterizing the effects of anti-PD1 immunotherapy on ataxia in a vestibular schwannoma mouse model.

Journal: Journal of neuro-oncology

Published: April 10, 2025

NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss.

NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss.

Journal: Nature communications

Published: March 04, 2025

Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model.

Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model.

Journal: bioRxiv : the preprint server for biology

Published: January 07, 2025

Synergistic blockade of TIGIT and PD-L1 increases type-1 inflammation and improves parasite control during murine blood-stage Plasmodium yoelii non-lethal infection.

Synergistic blockade of TIGIT and PD-L1 increases type-1 inflammation and improves parasite control during murine blood-stage Plasmodium yoelii non-lethal infection.

Journal: Infection and immunity

Published: September 26, 2024

Spatial gene regulatory networks driving cell state transitions during human liver disease.

Spatial gene regulatory networks driving cell state transitions during human liver disease.

Journal: EMBO molecular medicine

Published: September 26, 2024

Alternatively activated macrophages are associated with faster growth rate in vestibular schwannoma.

Alternatively activated macrophages are associated with faster growth rate in vestibular schwannoma.

Journal: Brain communications

Published: May 22, 2024

Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannoma.

Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannoma.

Journal: Nature communications

Published: May 09, 2024

The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis.

The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis.

Journal: Neuro-oncology advances

Published: June 08, 2023

Showing 1-12 of 13

Last Updated: 09/26/2026